-
Refining In Vitro Drug Response Assessment in Cancer Researc
2026-05-06
This dissertation by Hannah R. Schwartz critically re-examines how in vitro assays quantify anti-cancer drug responses, distinguishing between proliferative arrest and cell death. The study’s analytical approach clarifies that most compounds induce both effects, but with distinct magnitude and timing, revealing key limitations in conventional viability metrics and informing more accurate experimental design.
-
Annexin-V Mapping of Cardiomyocyte Death in Ischemia/Reperfu
2026-05-05
This study demonstrates the use of labeled recombinant human annexin-V for precise, in situ detection of early cardiomyocyte death in a mouse model of myocardial ischemia and reperfusion (I/R). The work defines the temporal dynamics of cell death and establishes annexin-V as a valuable tool for evaluating cell death–blocking interventions, with significant implications for cardiovascular research.
-
CD44-Driven Metabolic Rewiring in IDH-Mutant Leukemia
2026-05-05
This study uncovers how CD44 upregulation in IDH-mutant acute myeloid leukemia (AML) drives a unique metabolic dependency, sustaining NADPH generation for oncometabolite production. Targeting the CD44-mediated pathway presents a new vulnerability, with significant implications for combinatorial strategies in hematologic malignancies harboring IDH mutations.
-
ALDH2 Inhibition Triggers Synthetic Lethality in APC-Deficie
2026-05-04
A recent study demonstrates that inhibiting ALDH2 using disulfiram induces synthetic lethality in APC-deficient colorectal cancer via ROS/ASK1/JNK pathway activation. These findings highlight a genotype-selective vulnerability and suggest new avenues for targeted therapy in APC-mutant colorectal cancer.
-
SERL1–OsALDH2B1 Phosphorylation Drives Alkaline Tolerance in
2026-05-04
This study reveals that the SERL1 kinase phosphorylates and stabilizes OsALDH2B1, enhancing both alkaline tolerance and grain size in rice. The work uncovers a dual-function signaling module, providing a promising genetic target for developing stress-resilient, high-yield rice varieties.
-
A Tunable Human Intestinal Organoid Platform for Stemness an
2026-05-03
This study presents a modular organoid system that overcomes the longstanding challenge of balancing stem cell self-renewal and differentiation in human intestinal organoids. By leveraging small molecule pathway modulators, the authors achieve a scalable, reproducible platform with controllable cellular diversity, enabling robust high-throughput experimental applications.
-
Lysoptosis: Evolutionarily Conserved Cell Death via Serpin L
2026-05-02
This study defines lysoptosis as a distinct, evolutionarily conserved form of lysosome-dependent cell death, primarily regulated by intracellular serpins. The findings clarify the mechanistic separation of lysoptosis from other regulated cell death pathways and underscore the importance of serpin-cathepsin interactions for cellular survival.
-
SGI-1027 and Everolimus Synergy: Apoptosis and Pyroptosis in
2026-05-01
This study identifies SGI-1027 as a methuosis inducer that, in combination with everolimus, promotes apoptosis and GSDME-dependent pyroptosis in renal cell carcinoma by disrupting lysosomal membrane integrity. The findings provide a mechanistic rationale for combination therapy to overcome everolimus resistance in advanced RCC.
-
GLT-1 Upregulation Mitigates TBI via CB1-CREB Pathway Modula
2026-05-01
This study reveals that upregulating GLT-1 expression in mice with traumatic brain injury (TBI) reduces neuronal apoptosis and cognitive dysfunction by inhibiting the CB1-CREB signaling pathway. The findings clarify critical interactions between endocannabinoid signaling, astrocytic glutamate transport, and neuroprotection, highlighting mechanistic targets for TBI intervention.
-
Tirbanibulin Analogs as BoNT/A Inhibitors: Insights from KX2
2026-04-30
The reference study demonstrates that KX2-361, a structural analog of Tirbanibulin (KX2-391 dihydrochloride), inhibits botulinum neurotoxin serotype A (BoNT/A) activity in neuronal models, including both pre- and post-intoxication settings. This work advances the search for small-molecule BoNT/A inhibitors capable of acting within neurons, with implications for therapeutic development against botulism.
-
AmpliFold Strategy Boosts Lateral Flow Assay Sensitivity
2026-04-30
This study introduces the 'AmpliFold' capture-and-release workflow, significantly enhancing lateral flow assay (LFA) sensitivity by decoupling analyte capture from detection. The authors demonstrate that triggered release of analyte complexes enables high-affinity rebinding and up to 16-fold signal improvements, with broad implications for rapid diagnostic design.
-
Dual Enzyme-Responsive Zwitterionic Peptides for Cancer Sele
2026-04-29
This study introduces a zwitterionic peptide amphiphile that achieves high cancer selectivity by leveraging dual enzyme responsiveness for lysosomal self-assembly in cancer cells. The findings demonstrate a substantial increase in selectivity and therapeutic efficacy, with implications for the design of next-generation peptide-based chemotherapeutics.
-
MEK1/2-ERK1/2 Pathway Drives Lung Hemorrhage in Murine Lupus
2026-04-29
This study demonstrates that activation of the MEK1/2-ERK1/2 signaling axis is central to lung endothelial injury and impaired hemostasis leading to diffuse alveolar hemorrhage (DAH) in a murine lupus model. Pharmacological inhibition of MEK1/2 or ERK1/2, but not related MAPK pathways, effectively prevented DAH, offering mechanistic insight and translational relevance for future therapeutic strategy development.
-
Targeting BCL-XL and MCL-1 in Glioblastoma with BH3-Mimetics
2026-04-28
Koessinger et al. reveal that glioblastoma (GBM) cells exhibit elevated anti-apoptotic BCL-XL and MCL-1 expression, conferring heightened sensitivity to BH3-mimetic inhibitors. Their work demonstrates that sequential targeting of these proteins induces robust tumor apoptosis in preclinical models, advancing our understanding of apoptosis-based strategies for GBM therapy.
-
Octanoic Acid-Enriched Nutrition Modulates IBD via PPARγ/STA
2026-04-28
Xue et al. (2025) demonstrate that octanoic acid-rich enteral nutrition alleviates inflammatory bowel disease by reshaping intestinal macrophage polarization through the PPARγ/STAT-1/STAT-6 axis. Their mechanistic findings highlight metabolic-immune crosstalk as a therapeutic target and provide a validated framework for immunometabolic intervention studies.